Aileron Therapeutics is developing first-in-class Stapled Peptide therapeutics to engage disease targets and pathways that are undruggable by existing technologies. Stapled Peptide therapeutics have the potential to become a major class of drugs for oncology and other diseases. Aileron’s lead drug development candidate, ALRN-6924, is designed to reactivate wild-type p53, the body's first line of defense against cancer.
Apellis Pharmaceuticals is a clinical stage biopharmaceutical company treating autoimmune and inflammatory diseases by inhibition of the complement system, a cascade of interacting proteins and is an integral component of the immune system. The Apellis lead product candidates are being evaluated in clinical trials to treat ophthalmic, orphan and pulmonary conditions.
Founded by a highly experienced management team, Atea Pharmaceuticals, Inc. is an emerging biopharmaceutical company which is engaged in the discovery and development of novel antiviral therapeutics.
Bellicum (Nasdaq: BLCM) is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular therapies using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. The Company is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR T cell therapy, and dendritic cell vaccines.
Clearside Biomedical is developing first-in-class drug therapies to treat blinding diseases of the eye. Clearside’s clinical product candidates focus on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected non-surgically into the suprachoroidal space, or SCS, adjacent to the choroid, using the Company’s proprietary microinjector.
G1 Therapeutics is developing novel, small-molecule therapies that target cyclin-dependent kinases, or CDKs, a family of proteins that plays an important role in the growth and proliferation of cells. The company is advancing G1T28, a first-in-class drug candidate, and G1T38, a potential best-in-class compound, in multiple oncology indications.
Kezar Life Sciences
Kezar Life Sciences is discovering and developing innovative new therapies targeting protein homeostasis. Kezar’s lead program, KZR-616, is a selective inhibitor of the immunoproteasome for the treatment of autoimmune disorders. The work that led to KZR-616 was developed at Onyx Pharmaceuticals and Amgen by the Kezar scientific team that discovered and developed Kyprolis, a non-selective proteasome inhibitor for the treatment of malignancies. Kezar’s second program targets protein secretion, which is regulated by the Sec61 translocon on the endoplasmic reticulum.
Molecular Templates is focused on the discovery and development of a new class of Antibody Drug Conjugates (ADCs) with distinct advantages over existing ADC approaches. This biologic platform technology is being used to develop multiple therapies across a wide range of cancers. The Company’s lead compound, MT-3724, an immunotoxin targeting CD20, is in a Phase I study for the treatment of non-Hodgkin’s lymphoma and DLBCL.
Orionis Biosciences was founded in 2015 by an experienced management team with two platforms, one a small molecule drug discover platform and the other a platform focused on novel oncology therapeutics.
Selecta Biosciences is developing novel drugs that use immune modulating nanomedicines to generate targeted antigen-specific immune responses to prevent and treat disease. Selecta’s proprietary Synthetic Vaccine Particle (SVP) platform creates a novel paradigm in immunotherapeutics and vaccines, enabling completely new applications while offering the potential of improved efficacy and safety profiles. Selecta’s SVP is a product engine that has the potential to unlock the full therapeutic value of biologic therapies.
Trefoil Therapeutics is developing therapeutic agents for treatment of corneal endothelial dystrophy, specifically Fuchs’ dystrophy and other endothelial diseases of the eye. Patients with Fuchs’ dystrophy experience degenerative changes to the endothelium of the cornea. Normally, the endothelium contributes to proper vision by pumping excess fluid out of the eye that could cause corneal swelling. Fuchs’ corneal dystrophy leads to a decrease in corneal endothelial cell count and function, ultimately causing edema and loss of vision.
Synlogic is developing several programs categorized to inborn errors of metabolism, immunomodulation and metabolic disease which synthetic biotic can be used for the treatment.
FLX Bio, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of best-in-class, oral small molecule therapeutics for the treatment of cancers and other immune disorders. Our lead compounds inhibit the CCR4 pathway which plays a key role in both suppressing the immune response to cancer and in the initiation, progression and persistence of allergic inflammation. We leverage big data and proprietary informatics together with our advanced drug discovery capabilities and deep biology expertise, to develop therapeutics that address key pressure points in pathways that propagate an abnormal immune response.
Seer is a life sciences and health data company focused on capturing and translating deep molecular insights from the proteome to enable early detection of cancer and neurological diseases, drive earlier treatment, and improve patient outcomes.
Sutro Biopharma is a clinical stage company pioneering a compelling and unique way of discovering, developing and manufacturing therapeutics. Our focus is aimed primarily on next generation cancer and autoimmune therapeutics — Antibody Conjugates, Bispecific Antibodies and Cytokine derivatives. Unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell.
Arvinas is a biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. Our proprietary PROTACTM protein degraders, or Proteolysis-Targeting Chimera, work by inducing the cell’s own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins.
Kymera Therapeutics is pioneering a game-changing new therapeutic modality and platform with the potential to transform drug discovery and deliver breakthrough medicines for previously untreatable diseases. Kymera is focused on using targeted protein degraders to degrade proteins involved in the pathogenesis of inflammatory diseases and cancer.